Aberrant activation of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR, PAM) signaling is regarded as a crucial hallmark in a broad spectrum of human cancers (Folkes et al., 2008; Furet et al., 2013). The gene discussed is AKT1; the disease is cancer.